Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Egyesült Államok3. fázis

A Phase 3 Randomized Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidism

A legfontosabb adatok

Ki végzi
Ascendis Pharma Bone Diseases A/S
Hol
Chicago, Greeley, Greenville, Houston, Minneota, New Brunswick, New York, Reno és Spokane Valley (Egyesült Államok)Mind a 9 helyszín megnézése
Azonosító
Állapot
Toboroz
Fázis
3. fázis
Résztvevők
36 fő, tervezett
Kezdés
2026. máj. 7.
Várható befejezés
2028. jún.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • Palopegteriparatide Experimental Arm
  • Palopegteriparatide Control Arm
A regiszteradat frissítve
2026. november 5.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 22 feltétel megnézéseKevesebb

Ki vehet részt

  • Males and females, ≥18 years of age at the time of providing informed consent
  • Participants with postsurgical chronic hypoparathyroidism (HP), or auto-immune, genetic, or idiopathic HP, for at least 26 weeks
  • Receiving doses of palopegteriparatide at or above 30 µg/day; For individuals receiving 30 µg/day: evidence that dose is insufficient to keep serum calcium in the normal range, defined as:; Documented hypocalcemia within 12 weeks prior to Screening; and/or Standing dose of calcitriol ≥0.25 μg/day, and / or (elemental) calcium ≥1500 mg/day (e.g., calcium citrate, calcium carbonate etc.) for at least 4 weeks prior to Screening; For individuals receiving 33 µg/day or greater: no requirement for documented hypocalcemia or minimum doses of calcitriol or elemental calcium
  • Confirmation of laboratory parameters (Central or Local) within 2 weeks of screening visit and prior to randomization:; 25(OH) vitamin D levels of ≥ 20 ng/mL (≥49 nmol/L) and Magnesium level in the normal range, or just below the normal range i.e.: ≥1.3 mg/dL (≥0.53 mmol/L) and Albumin-adjusted or ionized sCa level in the normal range or just below the normal range
  • Albumin-adjusted sCa 7.8 - 10.6 mg/dL (or 1.95 - 2.64 mmol/L)
  • Ionized sCa 4.40 - 5.29 mg/dL (1.10 - 1.32 mmol/L); BMI 17- 40 kg/m2 at Screening; If ≤25 years of age, radiological evidence of epiphyseal closure based on locally interpreted X-ray of non-dominant wrist and hand; eGFR ≥30 mL/min/1.73 m2 during Screening using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula

Ki nem vehet részt

  • Use of thiazide diuretic within 4 weeks prior to the 24-hour urine collection scheduled to occur within 1 week prior to Visit 1
  • Use of PTH-like drugs other than palopegteriparatide (whether commercially available or through participation in an investigational trial), including PTH(1-34), or other N-terminal fragments, analogs of PTH or PTH-related protein, or PTH1R biased agonists within 4 weeks prior to Screening
  • Use of denosumab or romosozumab within 2 years prior to Screening. Use of raloxifene within 4 weeks prior to Screening
  • Non-hypocalcemic seizure disorder with occurrence of a seizure within 26 weeks prior to Screening
  • Diagnosed drug or alcohol dependence within 3 years prior to Screening
  • Chronic or severe cardiac disease within 26 weeks prior to Screening
  • Cerebrovascular accident within 5 years prior to Screening
  • Within 26 weeks prior to Screening: acute colic due to nephrolithiasis, or acute gout
  • Participation in any other interventional trial in which receipt of investigational drug or device other than palopegteriparatide occurred within 8 weeks (or within 5.5 times the half-life of the investigational drug) (whichever comes first) prior to Screening
  • Known allergy or sensitivity to PTH or any of the excipients [metacresol, mannitol, succinic acid, NaOH/(HCl)] of the investigational product
  • Any disease that might affect calcium metabolism or calcium-phosphate homeostasis or PTH levels other than HP
  • Use of loop diuretics, phosphate binders (other than calcium supplements), digoxin, lithium, methotrexate, biotin >30 µg/day, or systemic corticosteroids (other than as replacement therapy)
  • Use of drugs known to influence calcium and bone metabolism within 12 weeks prior to Screening
  • Impaired responsiveness to PTH (pseudohypoparathyroidism), which is characterized as PTH-resistance, with elevated PTH levels in the setting of hypocalcemia
  • Increased risk for osteosarcoma
  • Women who are pregnant, intend to become pregnant, or are lactating

Ez a vizsgálat jelenleg itt érhető el: Egyesült Államok.

  • Chicago, IllinoisHospital not named in the registryContact: Ascendis Registry InquiriesRésztvevőt keres
  • Greeley, ColoradoHospital not named in the registryContact: Ascendis Registry InquiriesRésztvevőt keres
  • Greenville, North CarolinaHospital not named in the registryContact: Ascendis Registry InquiriesRésztvevőt keres
  • Houston, TexasHospital not named in the registryContact: Ascendis Registry InquiriesRésztvevőt keres
  • Minneota, MinnesotaHospital not named in the registryContact: Ascendis Registry InquiriesRésztvevőt keres
  • New Brunswick, New JerseyHospital not named in the registryContact: Ascendis Registry InquiriesRésztvevőt keres
  • New YorkHospital not named in the registryContact: Ascendis Registry InquiriesRésztvevőt keres
  • Reno, NevadaHospital not named in the registryContact: Ascendis Registry InquiriesRésztvevőt keres
  • Spokane Valley, WashingtonHospital not named in the registryContact: Ascendis Registry InquiriesRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

This trial has a treatment duration of 78 weeks and will include adult participants already on treatment with palopegteriparatide at doses at or greater than 30 mcg/day. All participants will receive subcutaneous palopegteriparatide during the trial and will be individually and progressively titrated to an optimal dose at pre-specified dose levels. The primary purpose of the trial is to provide additional evidence of treatment effect and safety of palopegteriparatide at doses greater than 30 mcg/day in adults with hypoparathyroidism. The trial will be conducted in the US.

A vizsgálat 2 csoportja

  • Palopegteriparatide Experimental ArmA vizsgált kezelés

    Palopegteriparatide administered once daily by subcutaneous injection and titrated to an optimal dose by a novel titration algorithm.

  • Palopegteriparatide Control ArmMár használt kezelés, összehasonlításként

    Palopegteriparatide administered once daily by subcutaneous injection and titrated to an optimal dose by a previously evaluated titrated algorithm

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Phase 3, Multicenter, Randomized, Open-Label Trial Investigating the Safety, Tolerability and Efficacy of Palopegteriparatide Administered Subcutaneously Daily at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidism
A regiszteradat frissítve
2026. november 5.